Boots in Talks for $10 Billion Sale, Scrapping London IPO Plans
Key Developments in Boots' Strategic Sale Discussions
June 9 (Reuters) - Boots is in talks with the billionaire Weston family and Australian pharmacy group Sigma Healthcare over a $10 billion (£7.5 billion) sale that would see the British health and beauty retailer scrap its plans for a London IPO, the Financial Times reported on Tuesday, citing people familiar with the matter.
Background and Negotiation Details
Here are some details:
Sycamore Partners' Role
• Private equity firm Sycamore Partners, which took control of Boots last year through the $10 billion acquisition of its parent Walgreens Boots Alliance, entered into discussions with potential strategic buyers before Easter, the report said.
Weston Family and Sigma Healthcare Involvement
• Negotiations have progressed with the Canadian branch of the Weston family, which holds stakes in grocery chain Loblaws and pharmacy chain Shoppers Drug Mart through its Wittington Investments.
IPO Strategy and Alternative Options
• In April, Reuters reported that the Boots' owners are working with consultants on a strategy overhaul ahead of a potential London IPO as soon as 2027, which also included the possibility of a sale.
Boots' Market Presence and Services
Retail Footprint and Offerings
• Boots operates more than 1,800 stores across Britain, offering pharmacy services, health products and beauty brands including Soap & Glory. It is also a major provider of National Health Service-funded pharmacy services.
Responses and Comments
Statements from Involved Parties
• Sycamore declined to comment on the report, while Boots and Sigma Healthcare did not immediately respond to a Reuters request for comment. Wittington Investments could not be immediately reached for comment.
Reporting Credits
(Reporting by Unnamalai L and Akshaya V in Bengaluru; Editing by Sahal Muhammed)
